Mount Sinai Health System Jun 3 2026 Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile ( C. difficile ) infection. Their findings were published in the June 2 issue of Nature Medicine [10.1038/s41591-026-04442-2]. Recurrent C. difficile infection is a serious